46,XX difference of sex development induced by exogenous maternal-derived androgen is a genetic/congenital condition that affects body sex traits before birth. It happens when a fetus with two X chromosomes is exposed to higher levels of androgens from the mother or the placenta. Features can include genital changes seen at birth, with typical female internal organs, and later issues like irregular periods or excess body hair in adolescence. Many people with this condition are healthy and live a normal lifespan, but needs vary by how much androgen exposure occurred. Care often involves a team for evaluation, hormone monitoring, counseling, and, when needed, surgery or medicines to support development and well-being.
Overview
46,xx difference of sex development induced by exogenous maternal-derived androgenSymptoms
46,XX difference of sex development induced by exogenous maternal androgens shows at birth with atypical genital appearance—an enlarged clitoris, partial labial fusion, or a single opening. Internal female organs are typically present. Later, urinary or menstrual outflow issues may appear.
Outlook and prognosis
Many children with 46,XX difference of sex development induced by exogenous maternal-derived androgen grow and thrive, especially with early, coordinated care. Genital differences can be addressed over time, and fertility potential varies. Emotional wellbeing improves with supportive families and experienced specialists.
Causes and risk factors
46,xx difference of sex development induced by exogenous maternal-derived androgen stems from fetal exposure to maternal androgens in pregnancy, usually from androgenic medications, testosterone products, or maternal androgen‑secreting tumors. Risk increases with unprescribed hormones or contact with partner’s testosterone gel.
Genetic influences
Genetics matters, but exposure to androgens during pregnancy is the main driver in 46,XX difference of sex development induced by exogenous maternal-derived androgen. Most cases are not inherited. Still, genetic testing can clarify chromosomal sex and exclude other DSD causes.
Diagnosis
Suspected at birth from atypical genital findings. Diagnosis of 46,XX difference of sex development induced by exogenous maternal-derived androgen uses karyotype, hormone tests, maternal medication/tumor review, and pelvic imaging; genetic tests help exclude other causes, including congenital adrenal hyperplasia.
Treatment and drugs
Treatment focuses on lowering excess androgens, supporting genital development, and guiding puberty and fertility care. Options may include pausing exposure to androgen sources, tailored hormone therapy, and staged surgeries when appropriate. Ongoing psychosocial support and specialist follow-up are central.
Symptoms
Right after birth, the external genitals may look different than expected, which can be surprising and prompt careful evaluation. Clinicians call this 46,xx difference of sex development induced by exogenous maternal-derived androgen, which means a baby with two X chromosomes was exposed to higher levels of androgens from the mother during pregnancy. Most internal reproductive organs are typically female, and many aspects of growth and puberty later on are expected to be typical. Parents and clinicians often first notice early features of 46,xx difference of sex development induced by exogenous maternal-derived androgen in the newborn period.
At birth, the outer genitals may not look clearly male or female. Differences can range from mild changes to more obvious ones. This is often the first clue to 46,xx difference of sex development induced by exogenous maternal-derived androgen.
The clitoris may be larger than usual. This reflects the effect of androgens before birth. Sensation is typically preserved.
The labia may be partly fused in the midline. Urine may come from a single opening rather than two. This can make diaper changes or toileting a bit messier.
There may be a common channel for urine and vaginal fluid. In medical terms, this is a urogenital sinus; in everyday life, it shows up as differences in where the opening sits and how urine flows. Surgery may be considered to improve function later on.
How people usually first notice 46,xx difference of sex development induced by exogenous maternal-derived androgen?
Many families first notice something unusual at birth, when a newborn with 46,XX chromosomes has genitals that look more masculine than expected, such as a larger clitoris or fused labial folds; doctors may call this “virilization,” and it often prompts testing. Sometimes the first signs of 46,XX difference of sex development induced by exogenous maternal-derived androgen are flagged during pregnancy, for example if a parent used or was exposed to androgen-containing medications or if prenatal ultrasound suggests atypical genital development. In other cases, the appearance is subtle at birth and is picked up at the first pediatric visits, leading to evaluations that confirm the cause and guide care.
Types of 46,xx difference of sex development induced by exogenous maternal-derived androgen
People with 46,XX difference of sex development (DSD) from exogenous, maternal-derived androgens share the same chromosome pattern (46,XX) but differ in when and how much androgen exposure occurred before birth. This exposure can come from a mother’s medications or medical conditions that raise androgen levels during pregnancy, and timing often shapes which features appear. Symptoms don’t always look the same for everyone. When people talk about types of 46,XX DSD from outside-androgen exposure, they usually mean variants defined by timing, dose, and source—key drivers behind differences in genital appearance at birth, later puberty changes, and fertility potential.
Early-pregnancy exposure
Androgen exposure begins in the first trimester. This timing can affect genital formation more prominently at birth. Later growth and puberty may be closer to typical patterns if exposure was brief.
Mid-pregnancy exposure
Exposure starts in the second trimester. Newborn genital changes may be milder, with some features noticed only on exam. Puberty often proceeds typically, though some may have later cosmetic or functional concerns.
Late-pregnancy exposure
Exposure mainly occurs in the third trimester. Genital development at birth is usually typical, but there may be subtle changes like temporary swelling or pigmentation. Long-term hormone patterns are usually typical.
High-dose exposure
A higher androgen dose at any stage increases the chance of more noticeable genital differences at birth. Voice, body hair, or acne changes may appear later if exposure continued near late pregnancy. Not everyone will experience every type.
Maternal medication source
Androgens or androgen-like drugs taken during pregnancy are the source. Features depend on the drug strength, dose, and timing. If you notice one or more of these symptom types, bring it up at your next appointment.
Maternal tumor source
An ovarian or adrenal tumor in the mother produces excess androgens. Exposure can be sustained and significant until the tumor is treated. Early intervention during pregnancy can reduce ongoing exposure.
Maternal endocrine source
Maternal endocrine conditions (for example, certain adrenal disorders) raise androgen levels. The infant’s features depend on how well the condition was controlled in pregnancy. Share with your healthcare provider whether symptoms seemed to start early or later.
Transient placental transfer
Androgens cross the placenta briefly, such as after a short medication course. Features are often milder and more limited to birth findings. Types of 46,XX DSD from exogenous maternal-derived androgen often reflect this short, time-limited exposure.
What genetics can tell you about symptoms
Some babies with 46,XX DSD exposed to androgens during pregnancy can have genital changes at birth, like a larger clitoris or fused labial skin, because androgens act on developing tissues. Later, some may face earlier body hair, acne, or voice deepening, reflecting androgen effects.
Causes and risk factors
The main cause is exposure to androgens in the womb from the mother’s body or medications. When this exposure affects a baby with XX chromosomes, it is known medically as 46,XX difference of sex development induced by exogenous maternal-derived androgen. Doctors distinguish between risk factors you can change and those you can’t. Changeable risk factors for 46,XX difference of sex development include androgenic drugs or anabolic steroids, and contact with someone’s testosterone gel. Less changeable risks include a rare maternal ovarian or adrenal tumor that makes androgens, and the baby’s genes are usually normal.
Environmental and biological risk factors
46,XX difference of sex development induced by exogenous maternal-derived androgen occurs when a baby with XX chromosomes is exposed in the womb to higher-than-usual androgens coming from the mother or her treatments. Early symptoms of 46,XX difference of sex development induced by exogenous maternal-derived androgen are usually recognized at birth, but the drivers begin during pregnancy. Doctors often group risks into internal (biological) and external (environmental).
Medicines that act like male hormones (androgens), such as danazol, some high‑dose progestins, or testosterone products, can raise hormone levels in the pregnant body. If used in early pregnancy, these exposures can increase the chance of masculinizing changes in a 46,XX fetus.
Testosterone gels, creams, or sprays used by the pregnant person or a partner can transfer through skin contact or shared surfaces. Accidental absorption—like hugging soon after application or touching a contaminated towel—can lead to fetal exposure in early pregnancy.
Rare, pregnancy‑related ovarian growths can produce extra androgens. These growths (often benign) can temporarily raise hormone levels enough to affect genital development if they occur in the first trimester.
Disorders or tumors of the adrenal glands can increase circulating androgens in pregnancy. When this happens early in gestation, more androgens can reach the developing fetus.
Genetic risk factors
Genetic risk factors for 46,xx difference of sex development induced by exogenous maternal-derived androgen mostly come from inherited conditions in the pregnant parent that raise androgen levels during pregnancy. Some risk factors are inherited through our genes. These are typically autosomal recessive enzyme conditions grouped as congenital adrenal hyperplasia (CAH), which can run in families and vary in how strongly they affect hormones. Family history or ancestry patterns can offer clues about who may be at higher risk.
Maternal classic CAH: Classic 21-hydroxylase deficiency (a common form of CAH) can cause high androgen levels in pregnancy if the pregnant parent is affected. Those androgens can affect a 46,XX fetus’s external genital development. It follows an autosomal recessive inheritance pattern when both gene copies are changed.
Maternal nonclassic CAH: Nonclassic 21-hydroxylase deficiency is milder but can still raise androgen levels in some pregnancies. Some adults may not realize they have it until hormone changes during pregnancy bring it to light. It also runs in families through autosomal recessive inheritance.
11β-hydroxylase CAH: A rarer CAH type (11β-hydroxylase deficiency) can lead to maternal androgen excess during pregnancy. If the pregnant parent is affected, these hormones can influence fetal genital development. It is inherited in an autosomal recessive manner.
3-beta HSD deficiency: A rare CAH form (3-beta–HSD deficiency) can increase maternal androgen levels when the pregnant parent is affected. Like other CAH types, it is autosomal recessive.
Family history CAH: Having close relatives with CAH raises the chance that the pregnant parent carries or has an enzyme deficiency that elevates androgens. This increases the likelihood of in‑utero exposure for a future 46,XX fetus. Patterns can appear across generations due to recessive inheritance.
Parental consanguinity: When parents are related by blood, autosomal recessive conditions such as CAH are more likely to occur in the family. This can increase the chance the pregnant parent is affected and able to pass excess androgens during gestation.
Ancestry-linked variants: Some populations have higher rates of CAH-related gene changes, which can raise the likelihood that a pregnant parent is affected. These background patterns vary by region and family lineage.
Lifestyle risk factors
This is a congenital condition; lifestyle habits do not cause it. However, daily choices can influence symptoms, sexual function, bone health, and recovery after any procedures. The following points explain how lifestyle affects 46,xx difference of sex development induced by exogenous maternal-derived androgen. Tailoring habits to your anatomy, hormone profile, and care plan can improve comfort and long-term health.
Taking prescribed hormones, blockers, or topical treatments consistently supports bone health and symptom control. Skipping or stopping suddenly can trigger bleeding changes, hot flashes, or mood shifts that complicate care.
Weight-bearing and resistance exercise protect bone density if estrogen exposure is low or suppressed. Low-impact, pelvic floor–friendly movement can reduce pelvic pain and improve sexual function after genital surgery.
Adequate calcium, vitamin D, and protein help prevent bone loss when hormone levels fluctuate or are medically adjusted. Balanced meals also support energy and recovery after procedures.
Pelvic floor therapy and gentle stretches can ease urinary urgency and dyspareunia related to clitoromegaly, scarring, or prior reconstruction. Using lubricants or moisturizers can improve comfort with penetration.
Risk prevention
Most steps to prevent 46,xx difference of sex development induced by exogenous maternal-derived androgen focus on avoiding androgen exposure before and during pregnancy. Parents sometimes look for early symptoms of 46,xx difference of sex development, but prevention is mostly about planning and prompt prenatal care. These steps include careful medication choices, managing maternal health issues that raise androgen levels, and reducing everyday contact with hormone products. Knowing your risks can guide which preventive steps matter most.
Before trying to conceive, ask your clinician or pharmacist to review all prescriptions, over‑the‑counter drugs, and supplements for androgenic effects. Switching off drugs like danazol, anabolic steroids, certain progestins, or testosterone products ahead of time can lower the chance of 46,xx difference of sex development.
If you need a medicine with androgen effects, use reliable contraception and delay pregnancy until a safer alternative is arranged. This prevents fetal exposure during the earliest weeks, when 46,xx difference of sex development can start.
Book prenatal care as soon as pregnancy is suspected. Early visits allow fast medication changes and monitoring that reduce fetal androgen exposure and the risk of 46,xx difference of sex development.
Do not touch recently applied testosterone gels, creams, or sprays on others’ skin. Wash hands well, cover application sites, and keep products off shared surfaces and fabrics to prevent accidental exposure.
Transmission
46,XX difference of sex development induced by exogenous maternal-derived androgen is not contagious and cannot be passed from person to person. It is also not typically inherited; instead, it occurs during pregnancy if a developing baby with 46,XX chromosomes is exposed to higher-than-usual levels of male-type hormones (androgens) from the mother’s body or from medicines. This exposure can come from certain hormone medications or, rarely, from a hormone‑producing ovarian or adrenal tumor in the mother. There is no genetic transmission of 46,XX difference of sex development induced by exogenous maternal-derived androgen; most families have no prior history, and future risk depends on avoiding the same exposure and treating any maternal condition.
When to test your genes
Genetic testing can help if a newborn with 46,XX has genital ambiguity, atypical puberty, or unclear internal reproductive anatomy, especially when maternal androgen exposure is suspected. Test sooner if there’s rapid growth, early pubic hair, or salt-wasting concerns. Results guide hormone monitoring, imaging, and individualized care planning.
Diagnosis
Parents and clinicians usually first notice differences in the external genital area at birth, which prompts a focused evaluation. Getting a diagnosis is often a turning point toward answers and support. The diagnosis of 46,XX difference of sex development induced by exogenous maternal-derived androgen centers on confirming typical female chromosomes and internal organs while identifying prenatal androgen exposure. Tests also help rule out genetic and hormonal conditions that can look similar.
Clinicians assess the external genital appearance and check for findings like clitoromegaly or fused labial tissue. They also look for other features and overall health that might point to hormonal causes.
Providers review pregnancy exposures such as medications, supplements, or androgens and ask about maternal virilizing symptoms during pregnancy. They also consider maternal conditions like ovarian luteomas that can raise androgen levels.
Newborn bloodwork typically measures 17‑hydroxyprogesterone to rule out congenital adrenal hyperplasia and checks androgen levels like testosterone and androstenedione. Interpreting results alongside age and timing helps avoid false alarms.
A karyotype confirms 46,XX chromosomes, consistent with a genetic female. If results are unclear, chromosomal microarray may be used to look for subtler changes.
Stages of 46,xx difference of sex development induced by exogenous maternal-derived androgen
46,XX difference of sex development induced by exogenous maternal-derived androgen does not have defined progression stages. This pattern typically results from androgen exposure during pregnancy, so differences are usually present at birth rather than unfolding step by step over time. Different tests may be suggested to help confirm the cause, such as a careful newborn exam, hormone level checks, imaging to look at internal reproductive organs, a review of medicines or androgen sources during the pregnancy, and a chromosome check that often shows 46,XX. Doctors also look for early signs of 46,XX difference of sex development induced by exogenous maternal-derived androgen, then monitor growth and puberty over time to guide care and support.
Outlook and prognosis
Families often want to know how life will change when a baby is born with 46,XX difference of sex development induced by exogenous maternal-derived androgen. Day to day, the first questions usually focus on genital appearance, urination, and future fertility. Some newborns need no urgent treatment beyond careful evaluation, while others may benefit from staged care with a pediatric urologist, endocrinologist, and psychologist to support healthy development and family decision‑making. Everyone’s journey looks a little different.
Looking at the long-term picture can be helpful. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, but in this situation it’s also influenced by how long and how strongly the fetus was exposed to outside androgens during pregnancy. Early symptoms of 46,XX difference of sex development induced by exogenous maternal-derived androgen can include genital virilization at birth, yet internal reproductive organs are typically female, which may support future menstrual function and, in some cases, fertility. Many people find that symptoms related to body image or social stress improve with tailored counseling and peer support over time.
Mortality is generally not increased from the DSD itself when the cause is limited to maternal medication or androgen exposure and there are no other health conditions. Puberty often proceeds along a typical ovarian pathway, though some adolescents may need guidance around periods, contraception, or sexual function. Surgical decisions, if considered, are individualized and can be timed to prioritize safety, consent, and long-term outcomes; many families choose to delay irreversible procedures until the child can participate. With ongoing care, many people maintain good overall health and lead active lives, including sports, relationships, school, and work.
Talk with your doctor about what your personal outlook might look like.
Long-term effects
46,XX difference of sex development induced by exogenous maternal-derived androgen can have lasting effects that depend on how much androgen exposure happened and when during pregnancy. Long-term effects vary widely and can look different from one person to another. Many grow up with typical female puberty and overall health, while others may notice ongoing genital differences or voice and hair changes linked to early exposure.
External genitalia may stay more masculinized, such as a larger clitoris or a shared opening (urogenital sinus). These features can influence hygiene, sexual comfort, or medical exams.
Most experience typical breast development and regular periods. Early symptoms of 46,XX difference of sex development induced by exogenous maternal-derived androgen often appear at birth, but puberty itself is usually in the expected female pattern.
Ovaries and uterus are usually present and functional, so many can conceive. Some may face mechanical challenges related to genital anatomy rather than egg quality or hormone function.
Sensation is often intact, but genital shape or prior procedures can affect comfort and satisfaction. Open communication with clinicians can help identify anatomic reasons for pain or difficulty.
How is it to live with 46,xx difference of sex development induced by exogenous maternal-derived androgen?
Daily life with a 46,XX difference of sex development from maternal androgen exposure can be a mix of routine and extra planning around health checks, body changes, and identity questions. Some people navigate variations in genital appearance, menstruation, fertility, or hair growth, and may choose medical or surgical options over time, while others focus on comfort, function, and self-acceptance without interventions. Conversations with partners, family, and clinicians can be sensitive but also deeply supportive when handled with respect, clear information, and shared decision-making. Many find community—through peer groups or affirming care teams—helps turn uncertainty into confidence about their bodies, sexuality, and future.
Treatment and drugs
Treatment for 46,XX difference of sex development induced by exogenous maternal-derived androgen focuses on the child’s current health needs, future growth, and family goals, with care led by a specialized team that often includes endocrinology, urology/gynecology, psychology, and genetics. If genital changes are present, doctors may start with careful monitoring and, when needed, medicines that balance hormone levels; surgery, when considered, is individualized and typically timed to prioritize safety, function, and future decision‑making. As the child grows, puberty management may involve adjusting hormones to support typical development for someone with ovaries and a uterus, while preserving fertility potential when possible. Supportive care can make a real difference in how you feel day to day, including counseling for the child and family and clear, age‑appropriate information. Ask your doctor about the best starting point for you, since plans are tailored and may change over time.
Non-drug treatment
People with 46,xx difference of sex development induced by exogenous maternal-derived androgen may benefit from practical, supportive care that helps day-to-day life at each age. Alongside medicines, non-drug therapies can address emotional well-being, body comfort, and communication with the care team. Because early symptoms of 46,xx difference of sex development induced by exogenous maternal-derived androgen can be subtle, early referral and steady follow-up often make a difference. Care usually shifts over time—from family-focused support in infancy to body, sexual health, and reproductive counseling in adolescence and adulthood.
A coordinated team (endocrinology, urology/gynecology, psychology, genetics, nursing) helps align plans and timing. This approach supports shared decisions that fit your values and current needs. It also reduces information overload during stressful moments.
Mental health support can ease anxiety, stigma, or stress around medical visits and body changes. Sessions may include coping skills, resilience building, and support for parents or partners.
Clear, age-appropriate explanations help families talk confidently about the diagnosis at home and school. This is useful because early symptoms of 46,xx difference of sex development induced by exogenous maternal-derived androgen may be missed without guidance from the care team.
Connecting with others who have a similar DSD can reduce isolation and offer practical tips. Groups may meet online or locally and often include parents or partners.
Your genes may have an impact on how drugs work for you
Most medications for people with 46,XX DSD from maternal androgen exposure are chosen and dosed with genetics in mind, because genes can change how fast the body activates or clears a drug. Variants in enzymes like CYPs or receptors can shape effectiveness and side effects.
Pharmacological treatments
Because the androgen exposure comes from outside the baby and is temporary, people with 46,XX difference of sex development from maternal-derived androgens usually don’t need lifelong medicines. Care focuses first on the pregnant mother by stopping androgenic drugs and safely managing any condition making extra androgens. After birth, most children need no drug therapy; short courses may be used around procedures or based on individual needs and goals. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy).
Discontinue testosterone, danazol, or other androgenic medicines as soon as pregnancy is recognized under obstetric guidance. Safer alternatives can often be used instead, depending on why the medicine was started.
Drugs that block androgens such as spironolactone or flutamide are generally avoided while pregnant. If androgen-lowering therapy is needed after delivery for the mother, these can be considered with reliable contraception and specialist follow-up.
Hydrocortisone or other steroids are not indicated for the baby unless congenital adrenal hyperplasia is confirmed. Unnecessary steroids can affect growth and blood sugar, so doctors reserve them for clear medical need.
A short course of low-dose estradiol cream (for example, 0.01%) may be used before or after a chosen reconstructive procedure to soften tissues. This is optional and time-limited, guided by the surgical team.
Genetic influences
In 46,xx difference of sex development induced by exogenous maternal-derived androgen, the baby’s chromosomes are typically 46,XX, and the main driver is exposure to higher-than-usual androgens from the pregnant parent’s medicines or supplements during early pregnancy—not a gene change in the baby. Some people wonder if their condition could be “in the genes.” For this form of DSD, it usually isn’t inherited; family history doesn’t predict risk, and clinicians focus on what exposures occurred and when. The degree of changes at birth often relates to how much androgen was present and the timing of exposure, rather than differences in the child’s genes. Genetic testing for 46,xx difference of sex development induced by exogenous maternal-derived androgen is mainly used to confirm the 46,XX chromosome pattern and to rule out other inherited DSDs that can look similar. If the source of exposure is identified and avoided, the chance of the same issue in a future pregnancy is typically low.
Is 46,xx difference of sex development induced by exogenous maternal-derived androgen genetic?
Genetics matters, but exposure to androgens during pregnancy is the main driver in 46,XX difference of sex development induced by exogenous maternal-derived androgen. Most cases are not inherited. Still, genetic testing can clarify chromosomal sex and exclude other DSD causes.
Pharmacogenetics—how genetics influence drug effects
For people with 46,xx difference of sex development induced by exogenous maternal-derived androgen, most medicines relate to anesthesia and pain control around any procedures, and later routine gynecologic care, rather than lifelong hormone replacement. Genetic testing can sometimes identify how your body handles certain anesthetics or pain medicines, which can help tailor safer choices. For example, differences in a gene that turns codeine or tramadol into their active form can make these drugs either too weak or too strong, so doctors may choose a different pain reliever. Rare changes in the enzyme that clears succinylcholine, a muscle relaxant sometimes used during surgery, can cause slow recovery and prolonged weakness; if you or a close relative had this, your team may avoid that drug. If hormone therapy is used for menstrual regulation or acne, or an anti-androgen is considered for symptoms, genes that influence how quickly you process these medicines may affect dose, but factors like age, liver and kidney health, and other prescriptions usually play a larger role. In practice, doctors combine your history, prior drug reactions, and, when relevant, a pharmacogenetic result to personalize medication plans for 46,xx difference of sex development induced by exogenous maternal-derived androgen over time.
Interactions with other conditions
Families often face two layers at once: the baby’s genital differences and a mother’s health issue that caused the extra androgen exposure, such as a hormone-producing tumor or a medication taken during pregnancy. Some early features can look similar to congenital adrenal hyperplasia, a different condition that needs urgent attention because it can cause dangerous salt loss, so teams move quickly to sort this out. In the child, certain anatomic differences may raise the risk of urinary tract infections or make periods harder to manage later, but these are common problems with practical treatments. Emotional health matters too; stress around exams, sports, or changing rooms can add up, and counseling or peer support can make a real difference. Doctors call it a “comorbidity” when two conditions occur together, and if someone also has another endocrine issue (for example, a thyroid problem) or needs medicines for unrelated reasons, coordinated care helps keep treatments from working against each other. Because 46,xx difference of sex development induced by exogenous maternal-derived androgen is usually an isolated exposure rather than a genetic syndrome, it typically does not bring the extra heart, kidney, or learning concerns that sometimes travel with other DSDs.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of babies born with atypical genital appearance after certain medicines or environmental exposures during pregnancy. Midwives might recall that a few newborn girls in a village looked more male-appearing in some features during the years when a popular hormone pill was used, or when a relative worked in a setting with strong chemical fumes. These observations came long before anyone could measure hormone levels or name the condition.
First described in the medical literature as effects of “maternal androgens” on female fetuses, reports from the mid-20th century linked virilization in newborns with maternal use of androgenic drugs given for various pregnancy-related concerns. Later, clinicians documented similar findings in infants when a pregnant parent had tumors or medical conditions that raised androgen levels, or when high-dose progestins with androgen-like activity were prescribed. Over time, descriptions became more precise, separating infants with internal female reproductive organs (46,XX) from those with genetic or enzyme-related causes of similar features.
As medical science evolved, the idea of “exogenous” or outside-source androgens affecting a 46,XX fetus took clearer shape. Researchers compared cases across hospitals and countries, noting that the timing, type, and dose of exposure influenced how a child looked at birth. Early symptoms of 46,XX difference of sex development induced by exogenous maternal-derived androgen were recognized mainly through newborn appearance, while later follow-up showed how puberty and fertility could vary.
Once considered rare, now recognized as an important preventable cause, this form of 46,XX DSD moved from scattered case reports to a better understood category as prenatal care improved and potentially masculinizing medications in pregnancy were reduced or avoided. Historical case series helped establish that stopping exposure—by changing medications, treating a maternal tumor, or improving workplace protections—reduced new cases.
In recent decades, knowledge has built on a long tradition of observation. Imaging and chromosome testing allowed teams to confirm that affected infants had typical female internal organs and two X chromosomes, distinguishing them from other conditions. Endocrine testing clarified that the fetus itself did not overproduce androgens; the source was maternal. This sharpened counseling for families and guided safer prescribing during pregnancy.
Knowing the condition’s history reminds us why careful review of medications and maternal health during pregnancy matters. It also explains today’s emphasis on coordinated care—obstetrics, endocrinology, genetics, and urology or gynecology—so that people with 46,XX difference of sex development induced by exogenous maternal-derived androgen receive accurate diagnosis, thoughtful support, and follow-up tailored to their needs.